Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 31, Number 2—February 2025
Dispatch

Outbreak of Serotype 1 Invasive Pneumococcal Disease, Kibera Urban Informal Settlement, Nairobi, Kenya, 2023

Terry KomoComments to Author , Patrick K. Munywoki, Maria da Gloria Carvalho, Joshua Auko, Alice Ouma, Allan Audi, George O. Agogo, Daniel Omondi, Arthur Odoyo, Herine Odiembo, Newton Wamola, Mike Osita, Clayton Onyango, Naomi Lucchi, Peninah Munyua, Amy Herman-Roloff, Shanda Larson, Sopio Chochua, Fabiana C. Pimenta, Godfrey Bigogo, and Jennifer R. Verani
Author affiliation: Kenya Medical Research Institute, Kisumu, Kenya (T. Komo, J. Auko, A. Ouma, A. Audi, D. Omondi, A. Odoyo, H. Odiembo, N. Wamola, M. Osita, G. Bigogo); US Centers for Disease Control and Prevention, Nairobi (P.K. Munywoki, G.O. Agogo, C. Onyango, N. Lucchi, P. Munyua, A. Herman-Roloff); US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.D.G. Carvalho, S. Larson, S. Chochua, F.C. Pimenta, J.R. Verani)

Main Article

Table 2

Enrollment of SARI cases, pneumococcal carriage testing, and serotyping, Kibera Urban Informal Settlement, Nairobi, Kenya, January 1, 2018–August 20, 2024*

Year SARI cases NPs collected and tested Poor growth† Pneumococcus isolated‡ Serotyped ST1 Other PCV10 types§ Non-PCV10 types Serotype pending
2018 264 233 (88.3) 4 (1.7) 161/229 (70.3) 161 (100) 2 (1.2) 43 (26.7) 115 (71.4) 0
2019 318 312 (98.1) 0 174/312 (55.8) 174 (100) 4 (2.3) 33 (19.0) 137 (78.7) 0
2020 78 73 (93.6) 1 (1.4) 32/72 (44.4) 32 (100) 1 (3.1) 1 (3.1) 25 (78.1) 0
2021 133 110 (82.7) 11 (10.0) 40/99 (40.4) 39 (97.5) 0 7 (18.0) 31 (79.5) 1 (2.5)
2022 113 106 (93.8) 4 (3.8) 59/102 (57.8) 58 (98.3) 0 18 (31.0) 36 (62.1) 1 (1.7)
2023 125 120 (96.0) 11 (9.2) 58/109 (53.2) 56 (96.6) 10 (17.9) 13 (23.2) 21 (37.5) 2 (3.4)
2024 222 190 (85.6) 14 (7.4) 78/176 (44.3) 74 (94.9) 1 (1.4) 9 (12.2) 60 (81.1) 4 (5.1)

*Values are no. (row %) except as indicated. NP, nasopharyngeal swab sample; PCV10, 10-valent pneumococcal conjugate vaccine; PCV10-GSK, Synflorix 10-valent PCV (GlaxoSmithKline, https://www.gsk.com); PCV10-SII, (Pneumosil 10-valent PCV (Serum Institute of India, https://www.seruminstitute.com); SARI, severe acute respiratory illness; ST1, serotype 1. †Poor growth defined as <10 colonies of any bacteria. ‡Excludes samples with poor growth. §Includes serotypes common to PCV10-GSK and PCV10-SII (5, 6B, 7F, 9V, 15, 19F, and 23F), PCV10-GSK unique (4 and18C), and PCV10-SII unique (6A and 19A).

Main Article

Page created: January 02, 2025
Page updated: January 31, 2025
Page reviewed: January 31, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external